NOBIVAC FORCAT
Nazione: Paesi Bassi
Lingua: inglese
Fonte: HMA (Heads of Medicines Agencies)
Scheda tecnica
(SPC)
04-05-2012
Alcuni documenti per questo prodotto non sono attualmente disponibili, puoi inviare una richiesta al nostro servizio clienti e ti informeremo non appena saremo in grado di ottenerli.
Invia richiesta.
Invia richiesta.
Principio attivo:
chlamydophila felis (chlamydia psittaci) 10 Pfu, feline calicivirus 10 Pfu, feline herpesvirus 10 Pfu, Feline Panleucopaenia (Infectious Enteritis) Virus 10 Pfu
Commercializzato da:
Intervet Nederland B.V.
Codice ATC:
QI06AF01
Forma farmaceutica:
Powder and solvent for suspension for injection
Gruppo terapeutico:
Feline panleucopenia virus / parvovirus vaccine + Feline rhinotracheitis virus vaccine + Feline calicivirus vaccine + Chlamydia
Area terapeutica:
Cats Non Food
Data dell'autorizzazione:
2011-03-30
Scheda tecnica
SUMMARY OF PRODUCT CHARACTERISTICS
Nobivac Forcat (NL/V/0114/001/R/001)
– Renew al product literature (day 90) revised 300311
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Nobivac Forcat
(AT/DE: Nobivac RCP-Chlam)
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Per dose of 1 ml:
Lyophilisate:
ACTIVE SUBSTANCES:
live attenuated feline calicivirus, strain F9:
4.6 log
10
PFU
1
;
live attenuated feline herpes virus type 1, strain G2620A:
5.2 log
10
PFU
1
;
live attenuated feline panleucopenia virus, strain MW-1:
4.3 log
10
CCID
50
2
;
live attenuated _Chlamydophila felis_, strain Baker:
2.3 log
10
CCID
50
2
.
1
PFU: Plaque-Forming Units
2
CCID
50
: Cell Culture Infective Dosis 50%
EXCIPIENTS:
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Lyophilisate and solvent for suspension for injection.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cats
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Active immunisation of cats:
to reduce the clinical signs caused by infection with feline calicivirus and feline herpes virus type 1,
to reduce the severity of the clinical signs caused by infection with _Chlamydophila felis_,
to prevent the clinical signs, leucopenia and virus excretion caused by infection with feline
panleucopenia virus.
Onset of immunity: for FCV and FHV: 4 weeks; for FPLV and _C. felis_: 3 weeks.
Duration of immunity for FCV, FHV, _C. felis_: 1 year, for FPLV: 3 years.
4.3
CONTRAINDICATIONS
See section 4.7
Nobivac Forcat (NL/V/0114/001/R/001)
– Renew al product li
Leggi il documento completo
